J&J Reports Director Changes and Debt Issuances

Ticker: JNJ · Form: 8-K · Filed: 2025-06-10T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, debt-issuance, officer-changes

Related Tickers: JNJ

TL;DR

J&J's board is shuffling, and they just issued a bunch of new debt across various maturities.

AI Summary

Johnson & Johnson filed an 8-K on June 10, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also details various debt issuances, including notes due in 2028, 2029, 2032, 2033, 2035, 2036, 2037, 2044, and 2045, with interest rates ranging from 1.150% to 3.700%.

Why It Matters

This filing indicates changes in Johnson & Johnson's board and executive leadership, alongside significant debt financing activities which could impact the company's capital structure and future investments.

Risk Assessment

Risk Level: low — The filing primarily concerns routine corporate governance changes and debt issuance, which are standard disclosures for a company of this size.

Key Numbers

Key Players & Entities

FAQ

Who are the departing directors or officers mentioned in the filing?

The filing indicates the departure of directors and certain officers but does not name them specifically in the provided text.

What are the specific interest rates for the notes due in 2029?

The filing lists notes due February 2029 with an interest rate of 2.700% and notes due November 2028 with an interest rate of 1.150%.

What is the maturity date for the notes with a 3.200% interest rate?

The notes with a 3.200% interest rate mature in November 2032.

Are there any new officers appointed as part of these changes?

The filing mentions the appointment of certain officers as an item of disclosure, but specific names or details of appointments are not provided in this excerpt.

What is the total principal amount of the debt issued?

The filing lists various notes with their interest rates and maturity dates, but the principal amounts for these issuances are not detailed in the provided text.

From the Filing

0000200406-25-000152.txt : 20250610 0000200406-25-000152.hdr.sgml : 20250610 20250610170651 ACCESSION NUMBER: 0000200406-25-000152 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250610 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250610 DATE AS OF CHANGE: 20250610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 251037946 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 8-K 1 jnj-20250610.htm 8-K jnj-20250610 0000200406 false 0000200406 2025-06-10 2025-06-10 0000200406 us-gaap:CommonStockMember 2025-06-10 2025-06-10 0000200406 jnj:A1.150NotesDueNovember2028Member 2025-06-10 2025-06-10 0000200406 jnj:A2.700NotesDueFebruary2029Member 2025-06-10 2025-06-10 0000200406 jnj:A3.20NotesDueNovember2032Member 2025-06-10 2025-06-10 0000200406 jnj:A3.050NotesDueFebruary2033Member 2025-06-10 2025-06-10 0000200406 jnj:A1.650NotesDue2035Member 2025-06-10 2025-06-10 0000200406 jnj:A3.350NotesDueNovember2036Member 2025-06-10 2025-06-10 0000200406 jnj:A3.350NotesDueFebruary2037Member 2025-06-10 2025-06-10 0000200406 jnj:A3.550NotesDueNovember2044Member 2025-06-10 2025-06-10 0000200406 jnj:A3.600NotesDueFebruary2045Member 2025-06-10 2025-06-10 0000200406 jnj:A3.700NotesDueFebruary2055Member 2025-06-10 2025-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported):  June 10, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) One Johnson & Johnson Plaza , New Brunswick , New Jersey    08933   (Address of Principal Executive Offices)  (Zip Code)  Registrant's telephone number, including area code: 732 - 524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 1.150% Notes Due November 2028 JNJ28 New York Stock Exchange 2.700% Notes due February 2029 JNJ29B New York Stock E

View on Read The Filing